A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibitor

被引：0
|
作者：
Wang, J. [1 ]
Shen, Y. [1 ]
Chen, J. [2 ]
Chen, X. [3 ]
Guan, Q. [4 ]
Liu, Q. [5 ]
Xu, J. [6 ]
Xu, Y. [7 ]
Zhang, B. [8 ]
Zhang, H. [9 ]
Zhu, Y. [10 ]
Zhang, Y. [11 ]
机构：
[1] Jiangsu Canc Hosp, Gynecol, Nanjing, Peoples R China
[2] Second Peoples Hosp Changzhou, Gynecol, Changzhou, Jiangsu, Peoples R China
[3] First Peoples Hosp Yancheng, Gynecol, Yancheng, Peoples R China
[4] Jiangsu Hosp Tradit Chinese Med, Gynecol, Nanjing, Peoples R China
[5] Nanjing Med Univ, Jiangning Hosp, Gynecol, Nanjing, Peoples R China
[6] Subei Peoples Hosp Jiangsu Prov, Gynecol, Yangzhou, Jiangsu, Peoples R China
[7] First Peoples Hosp Changzhou, Gynecol, Changzhou, Jiangsu, Peoples R China
[8] Fourth Peoples Hosp Xuzhou, Xuzhou Cent Hosp, Gynecol, Xuzhou, Jiangsu, Peoples R China
[9] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Gynecol, Nanjing, Peoples R China
[10] Xuzhou Third Peoples Hosp, Xuzhou Canc Hosp, Gynecol, Xuzhou, Jiangsu, Peoples R China
[11] First Peoples Hosp Lianyungang, Gynecol, Lianyungang, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
202P
引用
收藏
页码：S1513 / S1513
页数：1
相关论文
共 50 条
  • [41] Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial
    Liu, Ming
    Qiu, Guihuan
    Guan, Wenhui
    Xie, Xiaohong
    Lin, Xinqing
    Xie, Zhanhong
    Zhang, Jiexia
    Qin, Yinyin
    Du, Haijian
    Chen, Xin
    Deng, Yu
    Li, Shiyue
    Zhong, Nanshan
    Zhou, Chengzhi
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [42] TISLELIZUMAB IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA: A SINGLE-CENTER, SINGLE-ARM, EXPLORATORY PHASE I I CLINICAL STUDY
    Laoguo, Shixue
    Huang, Huasheng
    Zeng, Jie
    Jiang, Yangfeng
    Liu, Cuizhen
    Mo, Ning
    Zhu, Guangzhi
    Ma, Fuchao
    Peng, Tao
    Yang, Lihua
    Zeng, Zhiming
    Ma, Jie
    HEPATOLOGY, 2023, 78 : S1904 - S1904
  • [43] EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
    Lheureux, Stephanie
    Oaknin, Ana
    Garg, Swati
    Bruce, Jeffrey P.
    Madariaga, Ainhoa
    Dhani, Neesha C.
    Bowering, Valerie
    White, Justin
    Accardi, Sarah
    Tan, Qian
    Braunstein, Marsela
    Karakasis, Katherine
    Cirlan, Iulia
    Pedersen, Stephanie
    Li, Tiantiam
    Farinas-Madrid, Lorena
    Lee, Yeh Chen
    Liu, Zhihui
    Pugh, Trevor J.
    Oza, Amit M.
    CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4206 - 4215
  • [44] Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-center, single-arm, phase II study
    Zhao, Y.
    Wang, L.
    Mao, A.
    Zhang, T.
    Pan, Q.
    Wang, L.
    Wang, Y.
    Lin, Z.
    Zhang, N.
    Zhou, J.
    Wang, M.
    Zhang, Y.
    Feng, Y.
    Ding, Z.
    Wang, Y.
    Li, Y.
    Wu, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S1458 - S1458
  • [45] Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
    Gaillard, Stephanie
    Duska, Linda
    Broadwater, Gloria
    McNally, Leah
    Lee, Paula
    Davidson, Brittany
    Previs, Rebecca
    Moss, Haley
    Berchuck, Andrew
    Nixon, Andrew
    Yi, John
    Bookman, Michael
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S61 - S62
  • [46] Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study)
    Kuang, Ming
    Xu, Lixia
    Zhang, Mengping
    Zheng, Gaomin
    Zhang, Chuankai
    Zhang, Ying
    Su, Tianhong
    Wang, Jifei
    Wang, Fang
    Wang, Fengjie
    Chen, Huanwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
    Lee, Yong Jae
    Lim, Myong Cheol
    Kim, Byoung Gie
    Ngoi, Natalie Yl
    Choi, Chel Hun
    Park, Sang Yoon
    Tan, David S. P.
    Go, Yunjung
    Lee, Jung Yun
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 32 (02) : 1 - 7
  • [48] Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study (vol 19, pg 1239, 2018)
    Lan, C-Y
    Wang, Y.
    Xiong, Y.
    LANCET ONCOLOGY, 2018, 19 (09): : E440 - E440
  • [49] Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study
    Zhu, Meiyan
    Liu, Zelong
    Chen, Shuling
    Luo, Zhenhua
    Tu, Jianfei
    Qiao, Liangliang
    Wu, Jian
    Fan, Wenzhe
    Peng, Zhenwei
    HEPATOLOGY, 2024, 80 (04) : 807 - 815
  • [50] Toripalimab combined with bevacizumab and chemotherapy as first-line treatment for refractory, recurrent or metastatic cervical cancer: a single-arm, open-label, phase II TRIA
    Li, Chen
    Peng, Peng
    Yao, Hairong
    Liu, Dantong
    He, Yonglan
    Liu, Shikai
    Cheng, Ninghai
    Cao, Dongyan
    Xiang, Yang
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A38 - A38
12345